Last reviewed · How we verify
nitroglycerin iv
At a glance
| Generic name | nitroglycerin iv |
|---|---|
| Also known as | nitropohl |
| Sponsor | Frisius Medisch Centrum |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Avelumab in Chemo-resistant Gestational Trophoblastic Neoplasias (PHASE2)
- NICardipine for Fast Achievement of Systolic BP Targets in ICH (PHASE4)
- Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6 (NA)
- Toripalimab Plus Actinomycin-D As Fist-Line Treatment for GTN with FIGO Score 7 (PHASE2)
- Nitroglycerin vs. Furosemide Using Lung Ultrasound Pilot Trial (PHASE2)
- Avelumab and Methotrexate in in Low-risk Gestational Trophoblastic Neoplasias as First Line Treatment (PHASE1, PHASE2)
- Gender Differences in Renal Functioning and Disease
- Upfront Premedication For Reduction of Microvascular Obstruction and No-reflow in Treating ST-segment Elevation Myocardial Infarction (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nitroglycerin iv CI brief — competitive landscape report
- nitroglycerin iv updates RSS · CI watch RSS
- Frisius Medisch Centrum portfolio CI